Parkman Healthcare Partners LLC Has $22.95 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Parkman Healthcare Partners LLC decreased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 42.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,031 shares of the biotechnology company's stock after selling 47,350 shares during the quarter. United Therapeutics comprises approximately 2.9% of Parkman Healthcare Partners LLC's investment portfolio, making the stock its 7th biggest holding. Parkman Healthcare Partners LLC owned about 0.14% of United Therapeutics worth $22,946,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Janus Henderson Group PLC grew its holdings in United Therapeutics by 12.3% during the third quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company's stock valued at $164,978,000 after purchasing an additional 50,409 shares during the period. HighTower Advisors LLC grew its holdings in United Therapeutics by 6.7% during the third quarter. HighTower Advisors LLC now owns 18,050 shares of the biotechnology company's stock valued at $6,493,000 after purchasing an additional 1,135 shares during the period. Hilltop Holdings Inc. bought a new position in United Therapeutics in the third quarter valued at approximately $209,000. Chevy Chase Trust Holdings LLC lifted its stake in United Therapeutics by 106.6% in the third quarter. Chevy Chase Trust Holdings LLC now owns 23,049 shares of the biotechnology company's stock valued at $8,260,000 after buying an additional 11,890 shares in the last quarter. Finally, Ascent Group LLC bought a new position in United Therapeutics in the third quarter valued at approximately $265,000. Institutional investors and hedge funds own 94.08% of the company's stock.

United Therapeutics Price Performance

NASDAQ UTHR traded up $5.61 on Wednesday, hitting $374.40. 151,166 shares of the stock were exchanged, compared to its average volume of 453,867. The business's fifty day moving average is $368.28 and its 200 day moving average is $337.45. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The company has a market capitalization of $16.72 billion, a PE ratio of 16.20, a P/E/G ratio of 1.08 and a beta of 0.54.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. During the same period in the previous year, the company earned $5.38 earnings per share. The company's quarterly revenue was up 22.9% on a year-over-year basis. Analysts predict that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In related news, EVP Paul A. Mahon sold 7,700 shares of the company's stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $367.36, for a total value of $2,828,672.00. Following the transaction, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $13,485,785.60. This represents a 17.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO James Edgemond sold 7,802 shares of the company's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the completion of the transaction, the chief financial officer now owns 3,210 shares in the company, valued at $1,108,766.10. This trade represents a 70.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 119,442 shares of company stock worth $44,577,770 over the last ninety days. Insiders own 11.90% of the company's stock.

Analyst Ratings Changes

A number of research analysts have weighed in on UTHR shares. TD Cowen lifted their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the company a "buy" rating in a research note on Monday, October 21st. LADENBURG THALM/SH SH lifted their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $350.00 to $380.00 and gave the company an "overweight" rating in a research note on Tuesday, August 20th. HC Wainwright boosted their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Finally, The Goldman Sachs Group boosted their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $370.86.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.